TNF Pharmaceuticals Salute del bilancio

Salute finanziaria criteri di controllo 5/6

TNF Pharmaceuticals has a total shareholder equity of $382.3K and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $26.4M and $26.0M respectively.

Informazioni chiave

Rapporto debito/patrimonio netto

US$0

Debito

Indice di copertura degli interessi	n/a
Contanti	US$13.07m
Patrimonio netto	US$382.29k
Totale passività	US$26.00m
Totale attività	US$26.38m

Aggiornamenti recenti sulla salute finanziaria

We Think MyMD Pharmaceuticals (NASDAQ:MYMD) Needs To Drive Business Growth Carefully

Sep 01

Recent updates

We Think MyMD Pharmaceuticals (NASDAQ:MYMD) Needs To Drive Business Growth Carefully

Sep 01

We're Keeping An Eye On MyMD Pharmaceuticals' (NASDAQ:MYMD) Cash Burn Rate

May 19

MyMD Pharma receives grant from European patent office for Supera-CBD compound

Aug 30

Oramed, MyMD surge on plans for early-stage oral COVID vaccine data release in Q3

Jul 08

Companies Like MyMD Pharmaceuticals (NASDAQ:MYMD) Could Be Quite Risky

Apr 12

MyMD Pharmaceuticals (NASDAQ:MYMD) Is In A Good Position To Deliver On Growth Plans

Aug 29

Analisi della posizione finanziaria

Passività a breve termine: TNFA's short term assets ($14.4M) exceed its short term liabilities ($5.8M).

Passività a lungo termine: TNFA's short term assets ($14.4M) do not cover its long term liabilities ($20.2M).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: TNFA is debt free.

Riduzione del debito: TNFA currently has no debt however we can't compare to 5 years ago as we have no data for that period.

Bilancio

Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: TNFA has sufficient cash runway for more than a year based on its current free cash flow.

Previsione Cash Runway: TNFA has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 10.2% each year.

TNF Pharmaceuticals Salute del bilancio

Salute finanziaria criteri di controllo 5/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

TNF Pharmaceuticals, Inc. announced delayed 10-Q filing

MyMD Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing

MyMD Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing

MyMD Pharmaceuticals Receives Non-Compliance Notice From Nasdaq

MyMD Pharmaceuticals Receives Non-Compliance Notice From Nasdaq

We Think MyMD Pharmaceuticals (NASDAQ:MYMD) Needs To Drive Business Growth Carefully

Recent updates

TNF Pharmaceuticals, Inc., Annual General Meeting, Nov 25, 2024

TNF Pharmaceuticals Prepares to Advance Lead Clinical Program Targeting Age-Related Decline

TNF Pharmaceuticals, Inc. announced delayed 10-Q filing

MyMD Pharmaceuticals Announces Executive Appointments

MyMD Pharmaceuticals, Inc. announced that it has received $14 million in funding from PharmaCyte Biotech, Inc.

MyMD Pharmaceuticals, Inc. announced that it expects to receive $14 million in funding from PharmaCyte Biotech, Inc.

MyMD Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing

MyMD Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing

New major risk - Market cap size

MyMD Pharmaceuticals, Inc. Plans FDA-Cleared Phase 2 Clinical Trial of MYMD-1 in Rheumatoid Arthritis

Mymd Pharmaceuticals, Inc. Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD, Reduced Acute Inflammatory Pain

MyMD Pharmaceuticals Receives Non-Compliance Notice From Nasdaq

MyMD Pharmaceuticals Receives Non-Compliance Notice From Nasdaq

MyMD Pharmaceuticals, Inc. to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF-a Market Disrupter, at BioFuture 2023

We Think MyMD Pharmaceuticals (NASDAQ:MYMD) Needs To Drive Business Growth Carefully

Chief Legal Officer recently bought US$167k worth of stock

FDA Accepts MyMD Pharmaceuticals, Inc. Investigational New Drug Application for Phase 2 Study of Oral Tnf-A Inhibitor Mymd-1®? in Rheumatoid Arthritis

Mymd Pharmaceuticals Reports Statistically Significant Positive Topline Phase 2 Results for Next Generation Oral Tnf-A Inhibitor Mymd-1® in Sarcopenia/Age-Related Frailty

New major risk - Share price stability

MyMD Pharmaceuticals, Inc., Annual General Meeting, Jul 31, 2023

We're Keeping An Eye On MyMD Pharmaceuticals' (NASDAQ:MYMD) Cash Burn Rate

MyMD Pharmaceuticals, Inc. to Present Data on Oral TNF-a Inhibitor MYMD-1 at the British Society for Immunology Congress 2022

MyMD Pharmaceuticals, Inc. Announces Publication of Phase 1 Data for Oral Tnf-Alpha Inhibitor Mymd-1® in Peer-Reviewed Journal Drug Research

MyMD Pharmaceuticals, Inc., Annual General Meeting, Dec 14, 2022

MyMD Pharmaceuticals, Inc. Provides Dosing Update on Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy Lifespan

MyMD Pharma receives grant from European patent office for Supera-CBD compound

MyMD Pharmaceuticals, Inc. Announces the Publication of Data in the Journal of Gerontology Biological Sciences (JGBS) from A Pre-Clinical Study of MYMD-1

MyMD Pharmaceuticals, Inc. Advances Phase 2 Multi-Center Clinical Trial of MYMD-1 as Therapy for Delaying Aging and Extending Healthy Lifespan

Oramed, MyMD surge on plans for early-stage oral COVID vaccine data release in Q3

MyMD Pharmaceuticals, Inc.(NasdaqCM:MYMD) dropped from Russell Microcap Value Index

MyMD Pharmaceuticals Advances Phase 2 Multi-Center Clinical Trial of MYMD-1 as A Therapy for Delaying Aging and Extending Healthy Lifespan

MyMD Pharmaceuticals’ Lead Compound MYMD-1 Demonstrates Superior Anti-inflammatory Effects over Top-Selling Therapies in a Pivotal Preclinical Model of Rheumatoid Arthritis

Companies Like MyMD Pharmaceuticals (NASDAQ:MYMD) Could Be Quite Risky

MyMD Pharmaceuticals, Inc Accelerates Pace of New Patient Dosing in Phase 2 Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan

MyMD Pharmaceuticals Inc Enrolls First Patient in Phase 2 Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan

MyMD Pharmaceuticals, Inc. Announces Positive Clinical Data in Advance of Upcoming Phase 2 Trial of MYMD-1 for Extending Healthy Lifespan

VP of Operations & General Counsel recently bought US$90k worth of stock

MyMD Pharmaceuticals Announces New Data Demonstrating 8,000 Times Higher Potency of Novel Synthetic Supera-CBD over Plant-Derived CBD

Less than half of directors are independent

MyMD Pharmaceuticals, Inc. Announces Fourth Quarter 2021 Initiation of Phase 2 Clinical Trial of MYMD-1 for Extending Healthy Lifespan

Less than half of directors are independent

Less than half of directors are independent

Independent Director Robert Schroeder has left the company

MyMD Pharmaceuticals (NASDAQ:MYMD) Is In A Good Position To Deliver On Growth Plans

MyMD Pharmaceuticals, Inc. announced delayed 10-Q filing

President exercised options and sold US$228k worth of stock

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Analisi della pista di contanti

Scoprire le aziende sane